Acrivon Therapeutics
ACRV
48 hedge funds and large institutions have $44.9M invested in Acrivon Therapeutics in 2025 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 10 reducing their positions, and 8 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 10
37% more capital invested
Capital invested by funds: $32.7M → $44.9M (+$12.2M)
3.27% more ownership
Funds ownership: 55.71% → 58.98% (+3.3%)
0% more funds holding
Funds holding: 48 → 48 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.06M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$753K |
| 3 |
Two Sigma Investments
New York
|
+$578K |
| 4 |
Two Sigma Advisers
New York
|
+$429K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$219K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Focus Partners Wealth
Boston,
Massachusetts
|
-$988K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$728K |
| 3 |
BlackRock
New York
|
-$274K |
| 4 |
Squarepoint
New York
|
-$170K |
| 5 |
Millennium Management
New York
|
-$138K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Focus Partners Wealth
Boston,
Massachusetts
| – | -$988K | -19,846 | Closed |
|
|
TRCT
52
Tower Research Capital (TRC)
New York
| – | -$15.8K | -8,736 | Closed |
|
|
CUAMC
53
China Universal Asset Management Company
Shanghai,
China
| – | -$9.98K | -5,514 | Closed |
|
54
Mirae Asset Global Investments
Seoul,
South Korea
| – | -$2.2K | -1,216 | Closed |
|
|
GFM
55
GF Fund Management
Guangzhou,
China
| – | -$1.18K | -650 | Closed |
|
ACRV Hedge Fund Activity: Q4 2025 in Review
48 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Acrivon Therapeutics (ACRV) for Q4 2025, worth a combined $44.9M — up 37% from $32.7M a quarter earlier.
Fund positioning in ACRV was balanced in Q4 2025: 8 funds opened new positions, 8 closed out, 16 added to existing stakes and 10 trimmed.
The largest buyer was Acadian Asset Management, adding an estimated $1.06M. The largest seller was Focus Partners Wealth, exiting entirely with an estimated $988K sold.
- 48 institutional investors held Acrivon Therapeutics (ACRV) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $44.9M of Acrivon Therapeutics stock for Q4 2025, up 37% quarter-over-quarter.
- 8 funds opened new Acrivon Therapeutics positions in Q4 2025 and 8 closed out, a net change of 0 holders.
- The largest Acrivon Therapeutics buyer in Q4 2025 was Acadian Asset Management, an estimated $1.06M added.
- The largest Acrivon Therapeutics seller in Q4 2025 was Focus Partners Wealth, an estimated $988K sold.
Based on aggregated 13F filings for Q4 2025.